BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 36898366)

  • 21. Updates in the Management of Primary Mediastinal B Cell Lymphoma.
    Soueidy C; Kourie HR
    Clin Lymphoma Myeloma Leuk; 2023 Dec; 23(12):866-873. PubMed ID: 37722943
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel Therapies Potentially Available for Pediatric B-Cell Non-Hodgkin Lymphoma.
    Harker-Murray PD; Pommert L; Barth MJ
    J Natl Compr Canc Netw; 2020 Aug; 18(8):1125-1134. PubMed ID: 32755987
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Clinical Characteristics and Prognosis of 56 Lymphoma Patients with Mediastinal Masses].
    Yu H; Wang L; Zhu HY; Wu W; Liang JH; Yin H; Fan L; Li JY; Xu W
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Apr; 28(2):495-499. PubMed ID: 32319385
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Addition of rituximab to CHOP-like chemotherapy in first line treatment of primary mediastinal B-cell lymphoma.
    Lisenko K; Dingeldein G; Cremer M; Kriegsmann M; Ho AD; Rieger M; Witzens-Harig M
    BMC Cancer; 2017 May; 17(1):359. PubMed ID: 28532396
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Programmed cell death-1 inhibitor combined with rituximab in refractory or relapsed diffuse large B-cell lymphoma: a preliminary efficacy and safety analysis].
    Qin Y; Zhao FY; Zhou Y; Jiang SY; Yang S; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2020 Dec; 42(12):1034-1039. PubMed ID: 33342160
    [No Abstract]   [Full Text] [Related]  

  • 26. Positron emission tomography after response to rituximab-CHOP in primary mediastinal large B-cell lymphoma: impact on outcomes and radiotherapy strategies.
    Vassilakopoulos TP; Papageorgiou SG; Angelopoulou MK; Chatziioannou S; Prassopoulos V; Karakatsanis S; Arapaki M; Mellios Z; Sachanas S; Kalpadakis C; Katodritou E; Leonidopoulou T; Kotsianidis I; Hatzimichael E; Kotsopoulou M; Dimou M; Variamis E; Boutsis D; Terpos E; Michali E; Karianakis G; Tsirkinidis P; Vadikolia C; Poziopoulos C; Pigaditou A; Vrakidou E; Siakantaris MP; Kyrtsonis MC; Symeonidis A; Anargyrou K; Papaioannou M; Chatziharissi E; Vervessou E; Tsirogianni M; Palassopoulou M; Gainaru G; Mainta C; Tsirigotis P; Assimakopoulou T; Konstantinidou P; Papadaki H; Dimopoulos MA; Pappa V; Karmiris T; Roussou P; Datseris I; Panayiotidis P; Konstantopoulos K; Pangalis GA; Rondogianni P
    Ann Hematol; 2021 Sep; 100(9):2279-2292. PubMed ID: 33523289
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of consolidative radiation therapy for patients with mediastinal diffuse large B-cell lymphoma in the rituximab era.
    Sert F; Kamer S; Saydam G; Anacak Y
    J Cancer Res Ther; 2018; 14(6):1397-1402. PubMed ID: 30488862
    [TBL] [Abstract][Full Text] [Related]  

  • 28. How I treat primary mediastinal B-cell lymphoma.
    Giulino-Roth L
    Blood; 2018 Aug; 132(8):782-790. PubMed ID: 29976557
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A single-institution retrospective analysis of outcomes for stage I-II primary mediastinal large B-cell lymphoma treated with immunochemotherapy with or without radiotherapy.
    Binkley MS; Hiniker SM; Wu S; Natkunam Y; Mittra ES; Advani RH; Hoppe RT
    Leuk Lymphoma; 2016; 57(3):604-8. PubMed ID: 26159046
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pembrolizumab in the treatment of refractory primary mediastinal large B-cell lymphoma: safety and efficacy.
    Camus V; Bigenwald C; Ribrag V; Lazarovici J; Jardin F; Sarkozy C
    Expert Rev Anticancer Ther; 2021 Sep; 21(9):941-956. PubMed ID: 34233557
    [No Abstract]   [Full Text] [Related]  

  • 31. Outcomes of treatment with dose-adjusted EPOCH-R or R-CHOP in primary mediastinal large B-cell lymphoma.
    Malenda A; Kołkowska-Leśniak A; Puła B; Długosz-Danecka M; Chełstowska M; Końska A; Giza A; Lech-Marańda E; Jurczak W; Warzocha K
    Eur J Haematol; 2020 Jan; 104(1):59-66. PubMed ID: 31606909
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas.
    Xie W; Medeiros LJ; Li S; Yin CC; Khoury JD; Xu J
    Curr Hematol Malig Rep; 2020 Aug; 15(4):372-381. PubMed ID: 32394185
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rituximab with standard LMB chemotherapy in pediatric high-risk mature B-cell non-Hodgkin lymphoma: A report from the JPLSG B-NHL14 trial.
    Mori T; Osumi T; Kada A; Ohki K; Koga Y; Fukano R; Fujita N; Mitsui T; Mori T; Saito AM; Nakazawa A; Kobayashi R; Sekimizu M
    Eur J Haematol; 2024 Apr; 112(4):585-593. PubMed ID: 38112205
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The molecular pathogenesis of primary mediastinal large B-cell lymphoma.
    Steidl C; Gascoyne RD
    Blood; 2011 Sep; 118(10):2659-69. PubMed ID: 21700770
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factors in 41 consecutive Asian patients.
    Tai WM; Quah D; Yap SP; Tan SH; Tang T; Tay KW; Koo YX; Tao M; Quek R; Lim ST
    Leuk Lymphoma; 2011 Apr; 52(4):604-12. PubMed ID: 21261504
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mediastinal Gray Zone Lymphoma with Features Intermediate between Classical Hodgkin Lymphoma and Primary Mediastinal B-Cell Lymphoma.
    Song HN; Kim SJ; Ko YH; Kim WS
    Acta Haematol; 2016; 136(3):186-90. PubMed ID: 27623181
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment strategies and survival outcomes of primary mediastinal large B-cell lymphoma.
    Quan L; He Z; Zuo X; Cao L; Wang Y; Dai H; Wu W; Shi X; Liu H
    Hematology; 2023 Dec; 28(1):2217396. PubMed ID: 37260259
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rituximab induction therapy, survival benefits, and the increasing selection of radiotherapy as the postinduction treatment in patients with primary mediastinal large B-cell lymphoma.
    Yang SH; Hsiao LT; Chiou TJ; Yang CF; Yu YB; Liu CY; Gau JP; Liu JH; Chen PM; Tzeng CH
    J Chin Med Assoc; 2015 Jul; 78(7):400-7. PubMed ID: 25801492
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcome and pathologic classification of children and adolescents with mediastinal large B-cell lymphoma treated with FAB/LMB96 mature B-NHL therapy.
    Gerrard M; Waxman IM; Sposto R; Auperin A; Perkins SL; Goldman S; Harrison L; Pinkerton R; McCarthy K; Raphael M; Patte C; Cairo MS;
    Blood; 2013 Jan; 121(2):278-85. PubMed ID: 23149845
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outcomes of Relapsed and Refractory Primary Mediastinal (Thymic) Large B Cell Lymphoma Treated with Second-Line Therapy and Intent to Transplant.
    Vardhana S; Hamlin PA; Yang J; Zelenetz A; Sauter CS; Matasar MJ; Ni A; Yahalom J; Moskowitz CH
    Biol Blood Marrow Transplant; 2018 Oct; 24(10):2133-2138. PubMed ID: 29909154
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.